论文部分内容阅读
目的观察安福隆联合拉米夫定与单用拉米夫定治疗慢性乙型肝炎的疗效对比。方法选择36例符合慢性肝炎诊断标准的患者,进行安福隆(IFNa—2b)联合拉米夫定(LAM)与单用拉米夫定(LAM)治疗各18例,对比观察其治疗效果。结果治疗6个月后肝功能2组间比较差异无显著性(P>0.05),而2组病例治疗后3、6和12个月HbeAg和HBVDNA阴转率,HbeAg/HbeAb血清转换率有差异显著性(联合组治疗后3、12个月比较:P=0.02046;单用组与联合组比较:P=0.0461)。结论联合用药治疗慢性乙型肝炎,不但可以提高疗效,同时可减少复发,缩短LAM的用药时间,为尽早停用LAM提供有力支持。
Objective To observe the efficacy of An Fulong combined with lamivudine and lamivudine in the treatment of chronic hepatitis B. Methods Thirty-six patients with chronic hepatitis were enrolled in the study. 18 patients were treated with IFNa-2b combined with lamivudine (LAM) and lamivudine alone (LAM). The therapeutic effect was observed. Results There was no significant difference in liver function between the two groups after 6 months of treatment (P> 0.05), while the rates of HbeAg and HBVDNA negative conversion and HbeAg / HbeAb seroconversion were different between the two groups at 3, 6 and 12 months Significance (3,12 months after treatment in the combined group: P = 0.02046; compared with the combined group: P = 0.0461). Conclusion Combined treatment of chronic hepatitis B can not only improve the curative effect, but also reduce recurrence, shorten the time of LAM treatment and provide strong support for the early withdrawal of LAM.